Search results
YOUR HEALTH: Solution to overlooking dangerous heart condition
WAFB Baton Rouge· 1 day agoDilated cardiomyopathy, or DCM, is an enlargement of the heart, leading to heart failure. Genetics...
Study provides first stratification of the risk of developing dilated cardiomyopathy in symptom-free...
Medical Xpress· 5 days agoDilated cardiomyopathy is the most frequent cause of heart failure in young people and is the...
Lexeo Therapeutics Announces License Agreement to Accelerate Development of LX2006 for the Treatment...
Morningstar· 5 days agoUnder the license agreement, Lexeo has acquired certain rights1 including rights to current and future data generated in an ongoing investigator-initiated Phase 1A trial of AAVrh.10hFXN to treat ...
Affinia Therapeutics to Present Data on Novel Cardiotropic and BBB-Penetrant AAV Capsids and...
WTNH-TV New Haven· 5 days agoAffinia Therapeutics ("Affinia"), an innovative gene therapy company with a proprietary platform for rationally designed adeno-associated virus (AAV) vectors and gene therapies for rare and ...
Heartfelt relief: USC transplant center opening in Las Vegas to ease burden for Nevadans
Las Vegas Sun· 1 day agoKeck Hospital of USC’s Chief of Operations Jon Reuter, front left, and Transplant Administrator Pat...
Community organizes drive-by parade to celebrate toddler's heart transplant journey
WTVD-TV 11 Raleigh-Durham· 22 hours agoA community in the Town of Leland recently organized a drive-by parade in honor of 18-month-old...
Intellia (NTLA) to Report Q1 Earnings: What's in the Cards?
Zacks· 2 days agoIntellia is collaborating with Regeneron for the development of its investigational in vivo genome-editing candidate, NTLA-2001. In March 2024, the company dosed the first patient in the phase ...
Blood Clot in Heart: Cardiac Thrombosis vs Coronary Thrombosis
Verywell Health via Yahoo News· 3 days agoIt's often caused when blood stagnates along parts of the heart that don't contract well or when foreign material exists in the heart. Risk factors include: Scarring from a previous heart attack ...
BioMarin drops drug programs in pipeline cull
BioPharma Dive via Yahoo Finance· 2 days agoTwo of the discontinued programs, BMN 355 for long-QT syndrome and BMN 365 for PKP2 arrhythmogenic cardiomyopathy, hadn’t yet been tested in humans. The...
RBC Capital bullish on Edgewise's 7500 cardiac program, raises stock price target By Investing.com
Investing.com· 5 days agoOn Monday, RBC Capital Markets adjusted its outlook on Edgewise Therapeutics (NASDAQ:EWTX), a...
